At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,069 enrolled
Drug / intervention
Rabeprazole sodium +1 moredrug
Likely dose
Rabeprazole sodium 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
In Brief
A Phase 3 clinical trial evaluating Rabeprazole sodium and Esomeprazole for Gastroesophageal Reflux Disease (GERD). Completed, enrolled 1,069 participants across 83 sites in 14 countries.
Detailed Summary
The purpose of this study is to investigate the efficacy (ie, healing and symptom relief) and safety of Rabeprazole Extended-Release (RAB ER) 50 mg versus Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive Gastroesophageal Reflux Disease (eGERD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux Disease (GERD)
CountriesArgentina, Australia, Bulgaria, Canada, Chile, Croatia, Estonia, France, Germany, Hungary, India, Latvia, Lithuania, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2008
First PostedApr 2008
Primary CompletionSep 2009
Study CompletionJan 2010
TodayJul 2026
First PostedApr 15, 2008
Enrollment StartFeb 1, 2008
Primary CompletionSep 1, 2009
Study CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 18.2 years ago
Interventions
Rabeprazole sodiumdrug
Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
Esomeprazoledrug
Esomeprazole 40 mg capsule, once daily for 4-8 weeks.